BSHI/BTS guidance on crossmatching before deceased donor kidney transplantation
| Autor: | A. Poles, T. Key, J. Martin, D. Keegan, P. Brookes, R. Fernando, S. Day, N. Diaz Burlinson, David Briggs, Derek Middleton, S. Lloyd, T. Rees, Sharon J. Peacock, Eva Santos-Nunez, D. Kallon, Michelle Willicombe, E. Lawson, J. McCaughan, Judith Worthington, B. Clark, Olivia Shaw, C. Collins, R. Battle, D. Sage, Susan V. Fuggle, A. Harmer, F. Partheniou, C. Callaghan, P. Dunn, Martin Barnardo |
|---|---|
| Přispěvatelé: | Peacock, S [0000-0002-4414-8432], Briggs, D [0000-0002-6796-7086], Clark, B [0000-0001-7243-1916], Middleton, D [0000-0002-6688-8642], Apollo - University of Cambridge Repository |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Immunology Human leukocyte antigen Kidney Patient safety HLA Antigens Genetics antibodies Medicine Sample Type Humans Intensive care medicine Molecular Biology Genetics (clinical) Kidney transplantation Deceased donor kidney business.industry Histocompatibility Testing Cold Ischemia Equity (finance) General Medicine medicine.disease virtual crossmatching Kidney Transplantation HLA Transplantation Blood Grouping and Crossmatching business |
| Zdroj: | International journal of immunogenetics. 49(1) |
| ISSN: | 1744-313X |
| Popis: | All UK H&I laboratories and transplant units operate under a single national kidney offering policy, but there have been variations in approach regarding when to undertake the pre-transplant crossmatch test. In order to minimize cold ischaemia times for deceased donor kidney transplantation we sought to find ways to be able to report a crossmatch result as early as possible in the donation process. A panel of experts in transplant surgery, nephrology, specialist nursing in organ donation and H&I (all relevant UK laboratories represented) assessed evidence and opinion concerning five factors that relate to the effectiveness of the crossmatch process, as follows: when the result should be ready for reporting; what level of donor HLA typing is needed; crossmatch sample type and availability; fairness and equity; risks and patient safety. Guidelines aimed at improving practice based on these issues are presented, and we expect that following these will allow H&I laboratories to contribute to reducing CIT in deceased donor kidney transplantation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text